Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

[Business Wire] – Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, . . . → Read More: Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1 Similar Articles: Market Update (NYSE:BMY): Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – One Factor Driving Bristol-Myers Squibb (BMY) Down Today Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Gains 6% on Promising Cancer Treatment, Upgrade